Protalix Q2 2026 net income $3.8 million; reaffirms 2026 revenue guidance
Protalix reported second-quarter 2026 total revenue of $19.9 million, up from $15.7 million a year earlier, and net income of $3.8 million, or $0.05 per share, compared with $164,000 in the same quarter of 2025. The company reaffirmed its full-year 2026 total revenue outlook of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone already received, and reported $40.7 million in cash and short-term deposits at June 30, 2026.
Key points
- Q2 2026 total revenue was $19.9 million versus $15.7 million in Q2 2025; sales of goods rose $4.4 million to $19.8 million, driven mainly by sales to Chiesi and Fiocruz (Brazil).
- Net income for the six months ended June 30, 2026 was $22.1 million, or $0.27 per diluted share, compared with a net loss of $3.5 million a year earlier; the period includes the $25.0 million Chiesi milestone.
- 2026 guidance reiterated: total revenue of $78.0 million to $83.0 million, with Elfabrio sales excluding milestones of $33.0 million to $35.0 million and Elelyso sales of $20.0 million to $23.0 million.
- Top-line results from the PRX-115 Phase 2 RELEASE trial are anticipated in the second half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.